MicroRNA-511 inhibits malignant behaviors of breast cancer by directly targeting SOX9 and regulating the PI3K/Akt pathway Retraction in /10.3892/ijo.2022.5413

Zhao,Yuying; Pang,Weifeng; Yang,Ning; Hao,Ling; Wang,Lei

doi:10.3892/ijo.2018.4576

MicroRNA-511 inhibits malignant behaviors of breast cancer by directly targeting SOX9 and regulating the PI3K/Akt pathway

Retraction in: /10.3892/ijo.2022.5413

Authors:
- Yuying Zhao
- Weifeng Pang
- Ning Yang
- Ling Hao
- Lei Wang
View Affiliations

Affiliations: Department of Medical Oncology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: September 27, 2018 https://doi.org/10.3892/ijo.2018.4576
Pages: 2715-2726

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Numerous studies have revealed that a subset of microRNAs (miRNAs) is aberrantly expressed in breast cancer. The dysregulation of miRNAs is involved in the tumorigenesis and progression of breast cancer due to their negative regulation of downstream target genes. Therefore, the identification of deregulated miRNAs in breast cancer may provide important insights into the diagnosis and treatment of patients with this disease. miRNA‑511 (miR‑511) has been identified to be deregulated in diverse human cancer types; however, neither the expression status nor the detailed roles of miR‑511 in breast cancer have been clarified. Thus, it was aimed to determine the expression of miR‑511 in breast cancer, examine the role in malignant progression and explore its downstream targets. The results of the present study revealed that the expression of miR‑511 was downregulated in breast cancer tissues and cell lines. Decreased expression of miR‑511 was significantly associated with lymph node metastasis and tumor stage in patients with breast cancer. Functional analyses revealed that restoring miR‑511 expression suppressed breast cancer cell proliferation and colony formation, promoted apoptosis and reduced metastasis in vitro, while it attenuated tumor growth in vivo. Additionally, it was revealed that SRY‑box 9 (SOX9) was a direct target gene of miR‑511 in breast cancer cells. SOX9 was upregulated in breast cancer tissues and its expression was inversely correlated with that of miR‑511. Furthermore, SOX9 inhibition simulated the tumor‑suppressive roles of miR‑511 overexpression in breast cancer cells, while SOX9 reintroduction partially rescued these effects of miR‑511. Notably, the upregulation of miR‑511 targeted SOX9 to deactivate the PI3K/Akt signaling in breast cancer in vitro and in vivo. In conclusion, miR‑511 was downregulated in breast cancer, and impeded its malignant progression by directly targeting SOX9 and regulating the PI3K/Akt pathway. Thus, miR‑511 is a potential therapeutic target in breast cancer.

View Figures

View References

1	DeSantis CE, Ma J, Goding Sauer A, Newman LA and Jemal A: Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 67:439–448. 2017. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar
3	Veronesi U, Boyle P, Goldhirsch A, Orecchia R and Viale G: Breast cancer. Lancet. 365:1727–1741. 2005. View Article : Google Scholar : PubMed/NCBI
4	Nakamura S, Yagata H, Ohno S, Yamaguchi H, Iwata H, Tsunoda N, Ito Y, Tokudome N, Toi M, Kuroi K, et al: Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer. 17:199–204. 2010. View Article : Google Scholar
5	Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
6	Weigelt B, Peterse JL and van ‘t Veer LJ: Breast cancer metastasis: Markers and models. Nat Rev Cancer. 5:591–602. 2005. View Article : Google Scholar : PubMed/NCBI
7	Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, et al: 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 28:16–33. 2017. View Article : Google Scholar : PubMed/NCBI
8	Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:92–105. 2009. View Article : Google Scholar :
9	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
10	Ma XP, Zhang T, Peng B, Yu L and Jiang K: Association between microRNA polymorphisms and cancer risk based on the findings of 66 case-control studies. PLoS One. 8:e795842013. View Article : Google Scholar : PubMed/NCBI
11	Singh T and Adams BD: The regulatory role of miRNAs on VDR in breast cancer. Transcription. 8:232–241. 2017. View Article : Google Scholar : PubMed/NCBI
12	Lü L, Mao X, Shi P, He B, Xu K, Zhang S and Wang J: MicroRNAs in the prognosis of triple-negative breast cancer: A systematic review and meta-analysis. Medicine (Baltimore). 96:e70852017. View Article : Google Scholar
13	Evans-Knowell A, LaRue AC and Findlay VJ: MicroRNAs and Their Impact on Breast Cancer, the Tumor Microenvironment, and Disparities. Adv Cancer Res. 133:51–76. 2017. View Article : Google Scholar : PubMed/NCBI
14	Cao MQ, You AB, Zhu XD, Zhang W, Zhang YY, Zhang SZ, Zhang KW, Cai H, Shi WK, Li XL, et al: miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. J Hematol Oncol. 11:122018. View Article : Google Scholar : PubMed/NCBI
15	Hu TB, Chen HS, Cao MQ, Guo FD, Cheng XY, Han ZB and Li MQ: MicroRNA-421 inhibits caspase-10 expression and promotes breast cancer progression. Neoplasma. 65:49–54. 2018. View Article : Google Scholar : PubMed/NCBI
16	Lv ZD, Yang DX, Liu XP, Jin LY, Wang XG, Yang ZC, Liu D, Zhao JJ, Kong B, Li FN, et al: MiR-212-5p Suppresses the epithelial-mesenchymal transition in triple-negative breast cancer by targeting Prrx2. Cell Physiol Biochem. 44:1785–1795. 2017. View Article : Google Scholar : PubMed/NCBI
17	He S, Wang G, Ni J, Zhuang J, Zhuang S, Wang G, Ye Y and Xia W: MicroRNA-511 inhibits cellular proliferation and invasion in colorectal cancer by directly targeting hepatoma-derived growth factor. Oncol Res, 2018 Oncol Res. Jan 10–2018.Epub ahead of print. View Article : Google Scholar
18	Fang Z, Zhang L, Liao Q, Wang Y, Yu F, Feng M, Xiang X and Xiong J: Regulation of TRIM24 by miR-511 modulates cell proliferation in gastric cancer. J Exp Clin Cancer Res. 36:172017. View Article : Google Scholar : PubMed/NCBI
19	Zhang C, Chi YL, Wang PY, Wang YQ, Zhang YX, Deng J, Lv CJ and Xie SY: miR-511 and miR-1297 inhibit human lung adenocarcinoma cell proliferation by targeting oncogene TRIB2. PLoS One. 7:e460902012. View Article : Google Scholar : PubMed/NCBI
20	Zhang SQ, Yang Z, Cai XL, Zhao M, Sun MM, Li J, Feng GX, Feng JY, Ye LH, Niu JQ, et al: miR-511 promotes the proliferation of human hepatoma cells by targeting the 3′UTR of B cell translocation gene 1 (BTG1) mRNA. Acta Pharmacol Sin. 38:1161–1170. 2017. View Article : Google Scholar : PubMed/NCBI
21	de Anda-Jáuregui G, Espinal-Enríquez J, Drago-García D and Hernández-Lemus E: Nonredundant, highly connected MicroRNAs control functionality in breast cancer networks. Int J Genomics. 2018:95853832018. View Article : Google Scholar : PubMed/NCBI
22	Chakravarty G, Moroz K, Makridakis NM, Lloyd SA, Galvez SE, Canavello PR, Lacey MR, Agrawal K and Mondal D: Prognostic significance of cytoplasmic SOX9 in invasive ductal carcinoma and metastatic breast cancer. Exp Biol Med (Maywood). 236:145–155. 2011. View Article : Google Scholar
23	Riemenschnitter C, Teleki I, Tischler V, Guo W and Varga Z: Stability and prognostic value of Slug, Sox9 and Sox10 expression in breast cancers treated with neoadjuvant chemotherapy. Springerplus. 2:6952013. View Article : Google Scholar
24	Müller P, Crofts JD, Newman BS, Bridgewater LC, Lin CY, Gustafsson JA and Ström A: SOX9 mediates the retinoic acid-induced HES-1 gene expression in human breast cancer cells. Breast Cancer Res Treat. 120:317–326. 2010. View Article : Google Scholar
25	Chakravarty G, Rider B and Mondal D: Cytoplasmic compartmentalization of SOX9 abrogates the growth arrest response of breast cancer cells that can be rescued by trichostatin A treatment. Cancer Biol Ther. 11:71–83. 2011. View Article : Google Scholar
26	Wang H, He L, Ma F, Regan MM, Balk SP, Richardson AL and Yuan X: SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/β-catenin activation in breast cancer. J Biol Chem. 288:6478–6487. 2013. View Article : Google Scholar : PubMed/NCBI
27	Fazilaty H, Gardaneh M, Akbari P, Zekri A and Behnam B: SLUG and SOX9 cooperatively regulate tumor initiating niche factors in breast cancer. Cancer Microenviron. 9:71–74. 2016. View Article : Google Scholar :
28	Jeselsohn R, Cornwell M, Pun M, Buchwalter G, Nguyen M, Bango C, Huang Y, Kuang Y, Paweletz C, Fu X, et al: Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. Proc Natl Acad Sci USA. 114:E4482–E4491. 2017. View Article : Google Scholar : PubMed/NCBI
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
30	Liu Z, Yan Y, Cao S and Chen Y: Long non-coding RNA SNHG14 contributes to gastric cancer development through targeting miR-145/SOX9 axis. J Cell Biochem. 119:6905–6913. 2018. View Article : Google Scholar : PubMed/NCBI
31	Xia S, Feng Z, Qi X, Yin Y, Jin J, Wu Y, Wu H, Feng Y and Tao M: Clinical implication of Sox9 and activated Akt expression in pancreatic ductal adenocarcinoma. Med Oncol. 32:3582015. View Article : Google Scholar
32	Drusco A and Croce CM: MicroRNAs and cancer: A long story for short RNAs. Adv Cancer Res. 135:1–24. 2017. View Article : Google Scholar : PubMed/NCBI
33	Kanwal R, Plaga AR, Liu X, Shukla GC and Gupta S: MicroRNAs in prostate cancer: Functional role as biomarkers. Cancer Lett. 407:9–20. 2017. View Article : Google Scholar : PubMed/NCBI
34	O’Bryan S, Dong S, Mathis JM and Alahari SK: The roles of oncogenic miRNAs and their therapeutic importance in breast cancer. Eur J Cancer. 72:1–11. 2017. View Article : Google Scholar
35	Zheng Q, Cui X, Zhang D, Yang Y, Yan X, Liu M, Niang B, Aziz F, Liu S, Yan Q, et al: miR-200b inhibits proliferation and metastasis of breast cancer by targeting fucosyltransferase IV and α1,3-fucosylated glycans. Oncogenesis. 6:e3582017. View Article : Google Scholar
36	Maimaitiming A, Wusiman A, Aimudula A, Tudahong T and Aisimutula D: WITHDRAWN: Downregulation of MicroRNA-152 and Inhibition of Cell Proliferation, Migration, and Invasion in Breast Cancer. Oncol Res, Oncol Res. Jun 15–2017.Epub ahead of print. View Article : Google Scholar : 032421
37	Wang J, Song C, Tang H, Zhang C, Tang J, Li X, Chen B and Xie X: miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. Breast Cancer Res. 19:722017. View Article : Google Scholar : PubMed/NCBI
38	Sui Y, Zhang X, Yang H, Wei W and Wang M: MicroRNA-133a acts as a tumour suppressor in breast cancer through targeting LASP1. Oncol Rep. 39:473–482. 2018.
39	Degli Esposti D, Aushev VN, Lee E, Cros MP, Zhu J, Herceg Z, Chen J and Hernandez-Vargas H: miR-500a-5p regulates oxidative stress response genes in breast cancer and predicts cancer survival. Sci Rep. 7:159662017. View Article : Google Scholar : PubMed/NCBI
40	Chen X, Wang L, Qu J, Guan NN and Li JQ: Predicting miRNA-disease association based on inductive matrix completion. Bioinformatics. Jun 22–2018.Epub ahead of print. View Article : Google Scholar
41	Chen X, Xie D, Wang L, Zhao Q, You ZH and Liu H: BNPMDA: Bipartite Network Projection for MiRNA-disease association prediction. Bioinformatics. 34:3178–3186. 2018. View Article : Google Scholar : PubMed/NCBI
42	Chen X and Huang L: LRSSLMDA: Laplacian regularized sparse subspace learning for MiRNA-disease association prediction. PLOS Comput Biol. 13:e10059122017. View Article : Google Scholar : PubMed/NCBI
43	You ZH, Huang ZA, Zhu Z, Yan GY, Li ZW, Wen Z and Chen X: PBMDA: A novel and effective path-based computational model for miRNA-disease association prediction. PLOS Comput Biol. 13:e10054552017. View Article : Google Scholar : PubMed/NCBI
44	Chen X, Xie D, Zhao Q and You ZH: MicroRNAs and complex diseases: From experimental results to computational models. Brief Bioinform. Oct 17–2017.Epub ahead of print. View Article : Google Scholar
45	Chen X, Huang L, Xie D and Zhao Q: EGBMMDA: Extreme gradient boosting machine for MiRNA-disease association prediction. Cell Death Dis. 9:32018. View Article : Google Scholar : PubMed/NCBI
46	Zhang HH, Pang M, Dong W, Xin JX, Li YJ, Zhang ZC, Yu L, Wang PY, Li BS and Xie SY: miR-511 induces the apoptosis of radioresistant lung adenocarcinoma cells by triggering BAX. Oncol Rep. 31:1473–1479. 2014. View Article : Google Scholar : PubMed/NCBI
47	Wang H, Leav I, Ibaragi S, Wegner M, Hu GF, Lu ML, Balk SP and Yuan X: SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res. 68:1625–1630. 2008. View Article : Google Scholar : PubMed/NCBI
48	Zhou CH, Ye LP, Ye SX, Li Y, Zhang XY, Xu XY and Gong LY: Clinical significance of SOX9 in human non-small cell lung cancer progression and overall patient survival. J Exp Clin Cancer Res. 31:182012. View Article : Google Scholar : PubMed/NCBI
49	Bruun J, Kolberg M, Nesland JM, Svindland A, Nesbakken A and Lothe RA: Prognostic significance of β-catenin, E-cadherin, and SOX9 in colorectal cancer: Results from a large population-representative series. Front Oncol. 4:1182014. View Article : Google Scholar